ANI Pharma (ANIP) Tops Q4 EPS by 8c

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $0.76, $0.08 better than the analyst estimate of $0.68. Revenue for the quarter came in at $94.2 million versus the consensus estimate of $85.19 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Lumentum shares rise on analyst upgrades, AI demand outlook
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold